Beta-1 Adrenergic Receptor Genotype Ser49gly Is Associated With Beta-Blocker Survival Benefit in Patients With Heart Failure

Talameh, Jasmine A.; Garrand, Amanda; Ghali, Jalal K.; Oren, Ron M.; Dunlap, Stephanie H.; Bakel, Adrian Van; Piña, Ileana L.; Patterson, J. Herbert; McGrew, Frank; Miller, Alan B.; Schwartz, Todd A.

doi:10.1016/s0735-1097(12)60862-6

Cited by 6 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The audience again considered the patient case using the concepts presented during presentation. The future directions of cardiovascular pharmacogenetics introduced β-blocker efficacy in heart failure [22,23], and the seminar concluded with a summary of all of the information presented.…”

Section: Pharmacogenetic Educationmentioning

confidence: 99%

Physicians’ Attitudes Toward Pharmacogenetic Testing Before and After Pharmacogenetic Education

Luzum

2016

Per. Med.

View full text Add to dashboard Cite

Aim:Our aim was to evaluate physicians' attitudes toward pharmacogenetic testing before and after pharmacogenetic education. Methods: In total, 12 physicians (∼40% response rate) completed a survey with eight questions on 10-point scales on their attitudes toward pharmacogenetic testing before and after a 1-h grand rounds presentation on pharmacogenetics. Differences in question scores overall, among training levels (resident/fellow/attending), and specific drugs (clopidogrel/simvastatin/warfarin) were assessed using Wilcoxon signed-rank and exact Kruskal-Wallis tests. Results & conclusion: The scores for all eight questions increased, with statistically significant (p < 0.05) increases for four out of eight questions. The scores were similar among training levels, but the postscores for clopidogrel were significantly higher than for simvastatin and warfarin. In conclusion, brief pharmacogenetic education can significantly affect physicians' attitudes toward pharmacogenetic testing.

show abstract

Section: Pharmacogenetic Educationmentioning

confidence: 99%

Physicians’ Attitudes Toward Pharmacogenetic Testing Before and After Pharmacogenetic Education

Luzum

2016

Per. Med.

View full text Add to dashboard Cite

show abstract

“…Lanfear et al 13 have studied the effect of beta-blocker in patients with heart failure and concluded that beta-blocker therapy is 5 times more effective in Ser49 homozygous which is in line with our findings. Talameh et al 14 also studied a similar patient subset and concluded that the survival benefit of beta-blocker therapy in heart failure patients is detected in Ser49 homozygous, not heterozygous. In our study, there was no significant impact of Arg389Gly polymorphism on heart rate and response to beta-blocker therapy.…”

Section: Discussionmentioning

confidence: 99%

Structural and Functional Impact of Adrenoceptor Beta-1 Gene Polymorphism in Patients with Hypertrophic Cardiomyopathy and Response to Beta-Blocker Therapy

Raimoglou

2024

Anatol J Cardiol

View full text Add to dashboard Cite

Background: Hypertrophic cardiomyopathy (HCM) is a genetically inherited cardiac disorder with diverse clinical presentations. Adrenergic activity, primarily mediated through beta-adrenoceptors, plays a central role in the clinical course of HCM. Adrenergic stimulation increases cardiac contractility and heart rate through beta-1 adrenoceptor activation. Beta-blocker drugs are recommended as the primary treatment for symptomatic HCM patients to mitigate these effects. Methods: This prospective study aimed to investigate the impact of common ADRB-1 gene polymorphisms, specifically serine–glycine at position 49 and arginine–glycine at position 389, on the clinical and structural aspects of HCM. Additionally, the study explored the association between these genetic variations and the response to beta-blocker therapy in HCM patients. Results: A cohort of 147 HCM patients was enrolled, and comprehensive assessments were performed. The findings revealed that the Ser49Gly polymorphism significantly influenced ventricular ectopic beats, with beta-blocker therapy effectively reducing them in Ser49 homozygous patients. Moreover, natriuretic peptide levels decreased, particularly in Ser49 homozygotes, indicating improved cardiac function. Left ventricular outflow obstruction, a hallmark of HCM, was also reduced following beta-blocker treatment in all patient groups. In contrast, the Arg389Gly polymorphism did not significantly impact baseline parameters or beta-blocker response. Conclusion: These results emphasize the role of the Ser49Gly polymorphism in the ADRB-1 gene in shaping the clinical course and response to beta-blocker therapy in HCM patients. This insight may enable a more personalized approach to managing HCM by considering genetic factors in treatment decisions. Further research with larger populations and longer follow-up periods is needed to confirm and expand upon these findings.

show abstract

“…In a prospectively recruited population of heart failure patients, Talameh et al showed that β 1 Ser49Ser homozygotes, but not Gly49 carriers, had enhanced survival response to β blocker therapy, using a larger population to corroborate previous findings that β blocker therapy has a greater influence on outcomes only in patients with Ser49Ser genotype. 31,57 Another recent genetic substudy looked at the impact of genotype on dose response in heart failure patients receiving metoprolol or carvedilol. 58 β 1 Arg389 homozygote patients had increased mortality and worsened quality of life from lower β blocker doses, whereas dose did not affect outcomes in Gly389 carriers.…”

Section: Beta Adrenergic Antagonistsmentioning

confidence: 99%

Pharmacogenomics in Heart Failure

Oni‐Orisan

Lanfear

2014

Cardiology in Review

View full text Add to dashboard Cite

Heart failure is becoming increasingly prevalent in the United States and is a significant cause of morbidity and mortality. Several therapies are currently available to treat this chronic illness; however, clinical response to these treatment options exhibit significant interpatient variation. It is now clearly understood that genetics is a key contributor to diversity in therapeutic response, and evidence that genetic polymorphisms alter the pharmacokinetics, pharmacodynamics, and clinical response of heart failure drugs continues to accumulate. This suggests that pharmacogenomics has the potential to help clinicians improve the management of heart failure by choosing the safest and most effective medications and doses. Unfortunately, despite much supportive data, pharmacogenetic optimization of heart failure treatment regimens is not yet a reality. In order to attenuate the rising burden of heart failure, particularly in the context of the recent paucity of new effective interventions, there is an urgent need to extend pharmacogenetic knowledge and leverage these associations in order to enhance the effectiveness of existing heart failure therapies. The present review focuses on the current state of pharmacogenomics in heart failure and provides a glimpse of the aforementioned future needs.

show abstract

Beta-1 Adrenergic Receptor Genotype Ser49gly Is Associated With Beta-Blocker Survival Benefit in Patients With Heart Failure

Cited by 6 publications

References 0 publications

Physicians’ Attitudes Toward Pharmacogenetic Testing Before and After Pharmacogenetic Education

Physicians’ Attitudes Toward Pharmacogenetic Testing Before and After Pharmacogenetic Education

Structural and Functional Impact of Adrenoceptor Beta-1 Gene Polymorphism in Patients with Hypertrophic Cardiomyopathy and Response to Beta-Blocker Therapy

Pharmacogenomics in Heart Failure

Contact Info

Product

Resources

About